Branded pharmaceutical manufacturers frequently offer “copay coupons” that insulate
consumers from cost-sharing, thereby undermining insurers’ ability to influence drug
utilization. We study the impact of copay coupons on branded drugs first facing generic
entry between 2007 and 2010. Read more.